Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TAK-188

Antibody-drug conjugate · Kills target cells, directed at C-C motif chemokine receptor 8 (CCR8) · developed by TAKEDA PHARMACEUTICAL CO

Phase 1/2 Most advanced trial

TAK Developer

1 Registered trials

What is TAK-188?

TAK-188 is an antibody-drug conjugate targeting CCR8 on tumor-infiltrating regulatory T cells. It depletes CCR8-positive immunosuppressive cells to reactivate antitumor immune responses. The drug is studied in advanced or metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: C-C motif chemokine receptor 8 (CCR8)
Mechanism: Kills target cells, directed at C-C motif chemokine receptor 8 (CCR8)
Pathways: antitumor immune response
Therapy area: Oncology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07205718	Phase 1/2	Advanced or Metastatic Solid Tumors	Recruiting	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid Tumors

Other drugs acting on CCR8

Denikitug Phase 2 Tagmokitug Phase 1

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind TAK-188

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z